CClinicalTrials.gg
RecruitingNCT06175104HeartGPSUpdated Jul 20, 2025

HeartGPS: A Study Exploring the Effects of a Psychological Intervention for Parents and Their Babies After Prenatal Cardiac Diagnosis

An interventional study of HeartGPS in Heart Defects, Congenital, Anxiety in Pregnancy and Depression, Postpartum, sponsored by Children's Hospital Medical Center, Cincinnati. Recruiting at 4 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-20.

Sponsored by Children's Hospital Medical Center, Cincinnati · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Babies with single ventricle congenital heart disease (SVCHD) are often diagnosed during pregnancy. While prenatal diagnosis has important clinical benefits, it is often stressful and overwhelming for parents, and many express a need for psychological support. HeartGPS is a psychological intervention for parents who receive their baby's diagnosis of SVCHD during pregnancy. It includes 8 sessions with a psychologist, coupled with tailored educational resources, and a personalized care plan. The intervention focuses on fostering parent psychological adjustment and wellbeing, and supporting parents to bond with their baby in ways that feel right for them. Through this study, the investigators will learn if HeartGPS is useful and effective for parents and their babies when it is offered in addition to usual fetal cardiac care. The investigators will examine the effects of the HeartGPS intervention on parental anxiety, depression, and traumatic stress; fetal and infant brain development; parent-infant bonding; and infant neurobehavioral and neurodevelopmental outcomes. The investigators will also explore mechanisms associated with stress biology during pregnancy, infant brain development and neurodevelopmental outcomes, and parent and infant intervention effects.

Read the detailed description

Maternal prenatal stress and anxiety can affect brain development in fetuses with and without congenital heart disease (CHD), influencing neurodevelopmental trajectories and establishing a neural basis for phenotypes associated with adverse mental health outcomes later in life. The prenatal period offers a critical window of opportunity, when ameliorating maternal psychological stress is likely to have enormous benefits for parents and their babies. Yet, there is a remarkable lack of prenatal interventions to support parent mental health and optimize child development during this period. This longitudinal randomized controlled trial compares a novel, 8-week, prenatally-delivered psychological intervention (called HeartGPS) to usual fetal cardiac care. In comparison with usual care, the study aims are to examine the effects of HeartGPS on: (1) maternal psychological distress (anxiety, depression, and traumatic stress) across the perinatal period; (2) fetal and infant brain development; (3) infant neurodevelopment; and (4) parent-infant behavioral synchrony. The study will also explore how neurobiological, psychological, behavioral, and social factors may explain intervention effects.

Across multiple sites, the investigators will enroll 104 mothers and their babies with single ventricle congenital heart disease to receive usual fetal cardiac care or usual fetal cardiac care plus the HeartGPS intervention. HeartGPS includes psychology sessions during pregnancy and the early postpartum period, coupled with tailored educational resources, and a personalized care plan to support longer-term parent, child, and family mental health and wellbeing. Maternal prenatal assessments will be performed at baseline (pre-randomization) and approximately 36-weeks gestation followed by maternal and infant assessments at approximately infant age 28-days, 6-months, and 12-months. Fetal neuroimaging will occur at approximately 36-weeks gestation and infant neuroimaging will take place at approximately infant age 28-days, using structural and functional magnetic resonance imaging (MRI). Placental tissue, maternal, paternal and infant blood, and maternal and infant saliva samples will also be collected. The primary outcomes for the trial are changes in maternal anxiety, depression, and traumatic stress scores from baseline to 6-months postpartum. Secondary outcomes include neonatal neurobehavior (NeoNatal Neurobehavioral Scale), infant neurodevelopment at 12 months (Bayley Scales of Infant Development), and mother-infant behavioral synchrony at 12 months (CARE-Index). In addition to rigorously testing a promising new therapy, this study will generate knowledge to accelerate treatments for maternal prenatal psychological stress and define mechanisms underlying the fetal origins of brain development and neurodevelopmental outcomes in CHD.

02

Conditions studied

  • Heart Defects, Congenital
  • Anxiety in Pregnancy
  • Depression, Postpartum
  • Trauma, Psychological
  • Neurodevelopmental Disorders

Keywords

  • Congenital Heart Disease
  • Prenatal
  • Mental Health
  • Neurodevelopment
  • Neurobehavior
  • Fetal Cardiology
  • Psychological Intervention
  • Mother-Infant Attachment
  • Mother-Infant Bonding
  • Medical Traumatic Stress
  • Neuroimaging
  • Brain Development
  • Fetal Neuroimaging
  • Perinatal Mental Health
  • Medical Psychology
03

In context

Heart Defects, Congenital

1,007 studies on the registry are indexed under Heart Defects, Congenital; 257 are open to participants now.

This study's planned enrollment of 50 is below the median of 60 across 524 interventional studies indexed under Heart Defects, Congenital.

Browse Heart Defects, Congenital studies →

Lead sponsor

Children's Hospital Medical Center, Cincinnati is the lead sponsor of 661 studies on the registry; 134 are open to participants now.

Of its 54 completed or terminated interventional studies of FDA-regulated products, 30 (56%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Pregnant person carrying a fetus diagnosed with single ventricle congenital heart disease (CHD).
  2. Single ventricle CHD diagnosis between 16 and 30 weeks gestation.
  3. Singleton pregnancy.
  4. Pregnant person is planning to continue with the pregnancy.
  5. Pregnant person is able to participate and complete study assessments in English.

Exclusion criteria

Exclusion Criteria

  1. Fetus with comorbid condition with a predictable adverse impact on neurodevelopment (e.g., DiGeorge Syndrome).
  2. Fetal or maternal medical condition determined by treating physician to be contraindicative to study participation.
  3. Parent with an untreated major psychiatric condition, substance use disorder, or other circumstances that would interfere with study engagement or safe participation in the trial.
  4. Parent with a moderate to severe intellectual disability.
  5. Parent age \<18 years.
  6. Surrogate for pregnancy.

Prenatal administration of oral or intravenous corticosteroids for fetal lung maturation will be recorded but are not a reason for exclusion.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    HeartGPS (Treatment Arm)

    Participants will receive usual fetal cardiac care plus the HeartGPS intervention. This is a novel psychological intervention leveraging virtual technology and user-centered design to reduce maternal psychological stress and anxiety after prenatal cardiac diagnosis and improve neurodevelopmental outcomes for infants with single ventricle CHD. GPS stands for: Guiding through emotions, Providing information and support, and Strengthening connections. The intervention includes sessions with a trained psychologist, coupled with tailored educational resources, and a personalized care plan to support longer-term parent, child, and family wellbeing.

    Behavioral: HeartGPS

  • No intervention
    Usual Fetal Cardiac Care (Control Arm)

    In the usual care arm, participants will receive the information, support, and resources currently offered by their fetal heart care team. This can include support from their doctor or nurse, a social worker, psychologist, or support group, as well as information booklets, websites, and other resources to help parents learn more about their baby's heart condition.

Interventions

  • BehavioralHeartGPS

    HeartGPS includes three key components: 1. Sessions with a psychologist trained to deliver the intervention using attachment-based and trauma-informed therapy techniques, coupled with mind-body skills. The intervention can be delivered in-person or via telehealth, in accordance with participants' preferences. 2. Educational resources, including a series of modules to complement the sessions and evidence-based tools to support psychological adjustment and coping, parent-infant bonding and attachment, and parent-clinician communication. 3. A personalized care plan, charting mental health care needs, goals, and preferences, with evidence-based strategies to support longer-term wellbeing.

06

What researchers measure

Primary outcomes

  1. Maternal anxiety symptoms

    Maternal anxiety symptoms will be measured using the validated, 20-item, self-report State-Trait Anxiety Inventory State subscale. Response options for each item range from 1 ('Not at all') to 4 ('Very much so'), yielding a total possible score ranging from 20 to 80, with higher scores indicating greater anxiety symptoms.

    Time frame: Baseline, 36 weeks gestation (approximate), infant corrected-age 28 to 56 days, 4 months postpartum (approximate), and infant age 12 months (approximate)

  2. Maternal depressive symptoms

    Maternal depressive symptoms will be measured using the validated, 10-item, self-report Edinburgh Depression Scale. Response options for each item range from 0 to 3, yielding a total possible score ranging from 0 to 30, with higher scores indicating greater depressive symptoms.

    Time frame: Baseline, 36 weeks gestation (approximate), infant corrected-age 28 to 56 days, 4 months postpartum (approximate), and infant age 12 months (approximate)

  3. Maternal traumatic stress symptoms

    Maternal traumatic stress symptoms will be measured using the validated, 20-item, self-report Posttraumatic Stress Disorder Checklist for Diagnostic Statistical Manual of Mental Disorders, 5th edition (DSM-5). Response options for each item range from 0 ('Not at all') to 4 ('Extremely'), yielding a total possible score ranging from 0 to 80, with higher scores indicating greater traumatic stress symptoms.

    Time frame: Baseline, 36 weeks gestation (approximate), infant corrected-age 28 to 56 days, 4 months postpartum (approximate), and infant age 12 months (approximate)

Secondary outcomes

  1. Infant neurobehavior

    Infant neurobehavior will be assessed using the NeoNatal Neurobehavioral Scale (NNNS-II). The NNNS-II examines infant neurobehavioral organization, neurological reflexes, motor development (active and passive tone), and signs of stress. Analysis of the NNNS-II is based on summary scores for attention (possible scores: 1-9), handling (0-1), self-regulation (1-9), arousal (1-9), excitability (0-15), lethargy (0-15), hypotonicity (0-10), hypertonicity (0-10), non-optimal reflexes (0-15), asymmetric reflexes (0-16), habituation (1-9), quality of movement (1-9), and stress-abstinence (0-1). Some items may not be administered due to infant sternal precautions. Each infant is assigned to a mutually exclusive profile (category) based on their pattern of scores across the summary scores.

    Time frame: Infant corrected-age 28 to 56 days

  2. Infant neurodevelopment

    Infant neurodevelopment will be assessed using the Bayley Scales of Infant Development - Fourth Edition (BSID-4). Cognitive, language, and motor domains will be assessed, as well as infant social-emotional and adaptive behavior development. For each subtest or subdomain the highest possible score is 19, and the lowest possible score is 1. Scores from 8 to 12 are considered average.

    Time frame: Infant corrected-age 12 months (approximate)

  3. Mother-infant dyadic synchrony

    Mother-infant dyadic synchrony will be assessed using a standardized, 3-minute, free-play observational procedure, called the Child-Adult Relationship Experimental (CARE) Index. Four aspects of affective attunement (facial expression, vocal expressions, position and body contact, expressions of affection), and three aspects of behavioral attunement (pacing of turns, control, choice of activity) will each be rated and combined to generate an overall dyadic synchrony score ranging from 0-14, with higher scores indicating greater synchrony.

    Time frame: Infant corrected-age 12 months (approximate)

Other outcomes

  1. Variation of prenatal cortisol levels in maternal saliva

    Maternal hypothalamic-pituitary-adrenal (HPA) axis functioning will be assessed using saliva sampling at 3 timepoints daily on two consecutive weekdays.

    Time frame: Baseline, 32 weeks gestation (approximate)

  2. Variation of cortisol levels in maternal and infant saliva

    Maternal and infant hypothalamic-pituitary-adrenal (HPA) axis functioning will be assessed using saliva sampling at 4 timepoints before and after the Child-Adult Relationship Experimental (CARE) Index.

    Time frame: Infant corrected-age 12 months (approximate)

  3. Structural and functional brain development

    Functional magnetic resonance imaging (fMRI) indices will be used to compare variations of fetal and infant structural and functional brain development.

    Time frame: Approximately 36 weeks gestation and infant corrected-age 28 to 56 days

07

Study locations

1 of 4 sites recruiting
  • Children's Hospital Los Angeles
    Los Angeles, California 90027, United States
    • Jodie Votava-Smith, MD · Contact · jvotavasmith@chla.usc.edu
    • Jodie Votava-Smith, MD · Principal investigator
    • Jay Pruetz, MD · Sub investigator
    Not yet recruiting
  • Children's Hospital Medical Center, Cincinnati
    Cincinnati, Ohio 45229, United States
    • Nadine A Kasparian, PhD · Contact · nadine.kasparian@cchmc.org · 513-636-5575
    • Nadine A Kasparian, PhD · Principal investigator
    • James F Cnota, MD · Principal investigator
    Recruiting
  • Sydney Children's Hospital
    Randwick, New South Wales 2031, Australia
    Not yet recruiting
  • The Children's Hospital at Westmead
    Westmead, New South Wales 2145, Australia
    Not yet recruiting
08

References and documents

Related links

Individual participant data

Plan to share: Yes — Participant data that underlie the results reported in the published paper, after deidentification (text, tables, figures, and appendices).

Supporting information: Study protocol

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06175104
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Collaborators
Children's Hospital Los Angeles, Sydney Children's Hospitals Network
Responsible party
Sponsor
First posted
Dec 18, 2023
Start date
Jul 14, 2025 (estimated)
Primary completion
Dec 2026 (estimated)
Completion
Dec 2027 (estimated)
Last update
Jul 20, 2025

Study contacts

Nadine A. Kasparian, PhD
Contact
nadine.kasparian@cchmc.org
513-636-5575
James F. Cnota, MD
Contact
james.cnota@cchmc.org
513-636-3868
Nadine A. Kasparian, PhD
principal investigator · Children's Hospital Medical Center, Cincinnati

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion